Literature DB >> 23706641

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients.

Eef Vanderhelst1, Elke De Wachter, Julie Willekens, Denis Piérard, Walter Vincken, Anne Malfroot.   

Abstract

BACKGROUND: Chronic airway infection with methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis (CF) is an increasing clinical problem, and therapeutic options are limited. Because chronic infection with MRSA can be associated with accelerated decline in lung function, eradication of MRSA is attempted in most CF centres today. The aim of this observational prospective cohort study was to determine whether it is possible to eradicate MRSA from airways of CF patients using prolonged oral antibiotic combination therapy together with topical decolonization measures.
RESULTS: Eleven CF patients, (median age: 9 years (range 1-43); median FEV1: 91%pred (95%CI 74%-100%pred)) who were chronically infected with MRSA, were treated daily for six months with rifampicin and fusidic acid orally. This study did not include a patient control group. Two patients had to switch to an alternative schedule, using rifampicin and clindamycin, due to the resistance pattern of MRSA. Topical decolonization measures were applied to all patients and included mupirocin-containing nasal ointment in both nostrils three times daily for five days and chlorhexidine hair and body wash once daily for five days. Microbiological eradication was achieved in all patients at the end of the six-month eradication protocol, even when significant time (range 18 months to 9 years) had elapsed since initial isolation. In only one patient MRSA reappeared in the six-month follow-up period after the initial study period. Side-effects, like nausea, vomiting and diarrhoea were seen in five out of eleven patients, but did not lead to therapy cessation.
CONCLUSION: Chronic MRSA infection can be eradicated from respiratory tract samples using a six month dual antibiotic regimen and topical MRSA decolonization measures.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706641     DOI: 10.1016/j.jcf.2013.04.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  Activity of antimicrobial peptides, alone or combined with conventional antibiotics, against Staphylococcus aureus isolated from the airways of cystic fibrosis patients.

Authors:  Katarzyna Garbacz; Wojciech Kamysz; Lidia Piechowicz
Journal:  Virulence       Date:  2016-07-22       Impact factor: 5.882

2.  Calling all hosts: Bacterial communication in situ.

Authors:  Jessica L Cleary; Alanna R Condren; Katherine E Zink; Laura M Sanchez
Journal:  Chem       Date:  2017-03-09       Impact factor: 22.804

3.  Molecular epidemiology of methicillin-resistant Staphylococcus aureus isolated in serial cultures from the respiratory tract of children with cystic fibrosis.

Authors:  Duha Al-Zubeidi; Patrick G Hogan; Mary Boyle; Carey-Ann D Burnham; Stephanie A Fritz
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

Review 4.  Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.

Authors:  Rashmi Ranjan Das; Sushil Kumar Kabra; Meenu Singh
Journal:  ScientificWorldJournal       Date:  2013-12-30

5.  MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Authors:  Emilie Vallières; Jacqueline C Rendall; John E Moore; John McCaughan; Anne I Hoeritzauer; Michael M Tunney; Joseph Stuart Elborn; Damian G Downey
Journal:  ERJ Open Res       Date:  2016-03-15

6.  Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.

Authors:  Rodrigo Abensur Athanazio; Luiz Vicente Ribeiro Ferreira da Silva Filho; Alberto Andrade Vergara; Antônio Fernando Ribeiro; Carlos Antônio Riedi; Elenara da Fonseca Andrade Procianoy; Fabíola Villac Adde; Francisco José Caldeira Reis; José Dirceu Ribeiro; Lídia Alice Torres; Marcelo Bicalho de Fuccio; Matias Epifanio; Mônica de Cássia Firmida; Neiva Damaceno; Norberto Ludwig-Neto; Paulo José Cauduro Maróstica; Samia Zahi Rached; Suzana Fonseca de Oliveira Melo
Journal:  J Bras Pneumol       Date:  2017 May-Jun       Impact factor: 2.624

Review 7.  Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis.

Authors:  Susanna Esposito; Guido Pennoni; Valeria Mencarini; Nicola Palladino; Laura Peccini; Nicola Principi
Journal:  Front Pharmacol       Date:  2019-08-07       Impact factor: 5.810

8.  The first report of Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) patients in Saudi Arabia.

Authors:  Hanaa Banjar; Hend Al-Qahtani; Waseem Yasin; Waad Al-Wgait; Hanan Al-Amer; Rawia Raja; Ali Al-Nakhli; Kawthar Karkour
Journal:  Int J Pediatr Adolesc Med       Date:  2019-10-31

Review 9.  Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Authors:  David Kh Lo; Marianne S Muhlebach; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-07-21

10.  Incidence and treatment of methicillin-resistant S. aureus infection in cystic fibrosis patients: a cohort study.

Authors:  Paloma Horejs Bittencourt; Carlos Sidney Silva Pimentel; Bianca Sampaio Bonfim; Paulo José Marostica; Edna Lúcia Souza
Journal:  Braz J Infect Dis       Date:  2016-10-15       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.